title: [Neovascularization corneal regression in patients treated with photodynamic therapy with verteporfin].
abstract: BACKGROUND
  Corneal neovascularization is a vision-threatening condition usually associated with inflammatory or infectious disorders of the ocular surface. One current treatment is photodynamic therapy, which uses a photosensitizer to occlude the vessel, is successfully produced microvascular thrombosis with minimal damage to surrounding normal tissue. The aim of this article is to quantitatively determine the percentage of regression of corneal neovascularization experienced by patients treated with photodynamic therapy with verteporfin.
  
  
  METHODS
  A before and after treatment; experimental, analytical, prospective and longitudinal.
  
  
  RESULTS
  Of the 25 new vessels analyzed, 8 glasses (32 %) had total occlusion one month after, 15 vessels (60 %) had a partial occlusion in the range of 15.3 to 85.1 %, and 2 vessels (8 %) worsening in corneal vascularization. The mean area of corneal neovascularization decreased significantly a 70 % from 0.147 ± 0.118 mm2 to 0.045 ± 0.046 mm2 (p < 0.0005) after photodynamic therapy. No side efects were reported.
  
  
  CONCLUSIONS
  Photodynamic therapy with verteporfin is a safe and effective method of reducing corneal neovascularization and can be used to inhibit angiogenesis in the cornea.
authors.affiliation: División de Oftalmología, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México, maxdiaz_7@hotmail.com.
authors.forename: César David
authors.initials: CD
authors.lastname: Díaz-Dávalos
authors.forename: Arturo
authors.initials: A
authors.lastname: Carrasco-Quiroz
authors.forename: Dirce
authors.initials: D
authors.lastname: Rivera-Díez
mesh_terms: D000328:Adult; D000368:Aged; D016510:Corneal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin
keywords: Corneal diseases; Corneal neovascularization; Corneal transplantation; Phototherapy